Skip to main content
SpringerLink
Log in

Personalizing MM Treatment: Gaps in Current Knowledge

  • Chapter
  • First Online:
Personalized Therapy for Multiple Myeloma

  • 734 Accesses

Abstract

Management of multiple myeloma has become more complex with advances in our understanding of disease biology and the availability of newer therapies. Clinicians should use the best available evidence and make personalized decisions for individual patients. There are several disease-, patient-, and treatment-related factors that go into planning a therapeutic strategy for a given patient. The present chapter discusses the gaps in our knowledge and potential ways in which data are being gathered for better informed treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N Engl J Med. 2016;375:1289–94.

    Article  PubMed  Google Scholar 

  2. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

    Article  CAS  PubMed  Google Scholar 

  3. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269–77.

    Article  CAS  PubMed  Google Scholar 

  4. Boyd KD, Ross FM, Chiecchio L, et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC myeloma IX trial. Leukemia. 2012;26:349–55.

    Article  CAS  PubMed  Google Scholar 

  5. Jacobus SJ, Kumar S, Uno H, et al. Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. Br J Haematol. 2011;155(3):340–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119:2100–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27:1738–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106:2156–61. doi:10.1182/blood-2005-02-0761.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–7.

    Article  CAS  PubMed  Google Scholar 

  11. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28:4630–4.

    Article  CAS  PubMed  Google Scholar 

  12. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119:940–8.

    Article  CAS  PubMed  Google Scholar 

  13. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621–34.

    Article  CAS  PubMed  Google Scholar 

  14. Touzeau C, Le Gouill S, Mahe B, et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica. 2017;102(3):e112–4.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120:1060–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911–20.

    Article  CAS  PubMed  Google Scholar 

  18. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Andrulis M, Lehners N, Capper D, et al. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3:862–9.

    Article  CAS  PubMed  Google Scholar 

  20. Morice WG II, Timm MM, Jevremovic D, Ketterling RP, Kumar S, Reichard KK. Plasma cell phenotyping and DNA content analysis by 8-color flow cytometry: a highly sensitive assay that simultaneously measures clonality, ploidy, and proliferation. Mod Pathol. 2013;26:349A–50A.

    Google Scholar 

  21. Hose D, Reme T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96:87–95.

    Article  PubMed  Google Scholar 

  22. Kumar S, Timm M, Lacy M, et al. Combining measurements of plasma cell apoptosis and proliferation in multiple myeloma identifies patients with poor survival. Blood. 2005;106:952A.

    Google Scholar 

  23. Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28:2060–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gonsalves WI, Morice WG, Rajkumar V, et al. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 2014;167:500–5.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol. 2005;23:5668–74.

    Article  PubMed  Google Scholar 

  26. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–7.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann-Intern-Med. 1989;110:521–5.

    Article  CAS  PubMed  Google Scholar 

  28. Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28:1599–605.

    Article  PubMed  Google Scholar 

  29. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118:4519–29.

    Article  CAS  PubMed  Google Scholar 

  30. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.

    Article  PubMed  Google Scholar 

  31. Majithia N, Vincent Rajkumar S, Lacy MQ, et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015;90:981–5.

    Article  CAS  PubMed  Google Scholar 

  32. Parrish C, Rahemtulla A, Cavet J, et al. Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma. Biol Blood Marrow Transplant. 2015;21:1330–4.

    Article  PubMed  Google Scholar 

  33. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents. Bone Marrow Transplant. 2015;50:204–8.

    Article  CAS  PubMed  Google Scholar 

  34. Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Venner CP, Connors JM, Sutherland HJ, et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leuk Lymphoma. 2011;52:34–41.

    Article  CAS  PubMed  Google Scholar 

  36. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  PubMed  Google Scholar 

  37. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35.

    Article  PubMed  Google Scholar 

  38. Paiva B, Garcia-Sanz R, San Miguel JF. Multiple myeloma minimal residual disease. Cancer Treat Res. 2016;169:103–22.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic, Rochester, MN, USA

    Shaji Kumar M.D.

Authors
  1. Shaji Kumar M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shaji Kumar M.D. .

Editor information

Editors and Affiliations

  1. Department of Hematologic Oncology and Blood, Levine Cancer Institute, Charlotte, North Carolina, USA

    Saad Z. Usmani

  2. Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

    Ajay K. Nooka

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kumar, S. (2018). Personalizing MM Treatment: Gaps in Current Knowledge. In: Usmani, S., Nooka, A. (eds) Personalized Therapy for Multiple Myeloma. Springer, Cham. https://doi.org/10.1007/978-3-319-61872-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-61872-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-61871-5

  • Online ISBN: 978-3-319-61872-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation